Ake­bia adds $50M deal with Vi­for for ex­clu­sive US dis­tri­b­u­tion deal for vadadu­s­tat

Ake­bia keeps stack­ing up the mon­ey deals for its close­ly-watched ane­mia drug.

In the lat­est deal an­nounced af­ter the mar­ket closed Mon­day, Vi­for Phar­ma said it is buy­ing a $50 mil­lion stake in Ake­bia $AK­BA in ex­change for an ex­clu­sive US dis­tri­b­u­tion deal for their late-stage ane­mia drug vadadu­s­tat. Vi­for is pay­ing $14 a share in the deal to gain dis­tri­b­u­tion rights to the drug for its Fre­se­nius Med­ical Care dial­y­sis clin­ics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.